Shed vs Omzo: Coaching and Compounded GLP-1 Compared
Shed vs Omzo is a direct comparison between two telehealth weight loss platforms that both offer GLP-1 treatment options but differ in medication mix, coaching, and pricing. Early verdict: choose Shed if you want integrated continuous coaching and the option of name-brand GLP-1; choose Omzo if you prefer clinician-guided compounded plans with a lower starting price.
Explore Shed plans and coaching
Shed vs Omzo: top differences at a glance
This comparison focuses on the most distinctive differences supported by the sources: medication types offered, coaching and care model, starting price and offers, clinician review and prescribing approach, and regulatory notes about compounded medications.
1. Medication mix: name-brand plus compounded vs primarily compounded
Shed uniquely offers both FDA-approved name-brand GLP-1 options and compounded alternatives on one platform. Omzo primarily connects patients to compounded semaglutide and tirzepatide programs and notes that if a branded medication is prescribed the patient must fill it at a pharmacy because Omzo does not sell or ship branded drugs. Both platforms state that compounded medications are not FDA-approved.
2. Coaching and care model
Shed integrates continuous coaching into treatment, branding itself as more than a prescription and positioning coaching as part of the bundled program. Omzo describes clinician-guided plans reviewed by licensed U.S. providers and emphasizes provider judgment for prescriptions, but captured evidence does not indicate continuous coaching is integrated the same way as Shed.
3. Pricing and promotions
Shed lists compounded semaglutide starting at $199/month and compounded tirzepatide starting at $299/month and advertises 10% off your first month. Omzo shows semaglutide starting at $179 and tirzepatide starting at $279. Shed also notes that standard pricing is not fully published and that patients receive personalized quotes after intake.
4. Clinician review and how prescriptions are handled
Both platforms require clinician review. Shed uses a 2-minute approval assessment and issues prescriptions only after a licensed clinician determines treatment is appropriate. Omzo connects users with licensed medical providers who determine eligibility and make the final prescribing decision; Omzo states its assessment does not create a doctor patient relationship and that clinical services are provided by third party clinician networks.
5. Regulatory notes and pharmacy model
Both sources explicitly state that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality. Omzo adds that its compounded drugs are prepared by state licensed sterile compounding pharmacies and that it does not produce or manufacture medications. Shed similarly notes compounded medications are prepared by a licensed pharmacy and are not FDA-approved.
Comparison table: Shed vs Omzo
| Criteria | Shed | Omzo |
|---|---|---|
| Starting price | Compounded semaglutide starting at $199/month; compounded tirzepatide starting at $299/month; 10% off first month | Semaglutide starting at $179; tirzepatide starting at $279 |
| Medication types | Offers both FDA-approved name-brand GLP-1 and compounded options | Primarily compounded semaglutide and tirzepatide; branded prescriptions must be filled by patient at a pharmacy |
| Coaching and support | Continuous coaching integrated into treatment | Clinician-guided plans reviewed by licensed providers; coaching not described as integrated the same way in captured evidence |
| Approval process | 2-minute online assessment followed by clinician review before prescription | Assessment connects you to licensed clinicians who determine eligibility and prescribing |
| Regulatory note | Compounded medications are not FDA-approved | Compounded medications are not FDA-approved; produced in state licensed sterile compounding pharmacies |
| Best for | Patients who want more than a prescription and value integrated coaching | People who want clinician-guided compounded plans and should confirm eligibility, cost, and state availability first |
See Omzo clinician-guided plans
How the two compare in practice
If you prioritize access to both name-brand and compounded GLP-1 with integrated behavioral support, Shed presents that combination directly on its platform. If your priority is a lower advertised starting price for compounded semaglutide and explicit clinician-guided prescriptions that are produced by compounding pharmacies, Omzo documents that approach and notes FSA and HSA eligibility for some plans. Both require clinician review and both caution that compounded medications are not FDA-approved.
Both platforms include qualifiers about results and regulatory status. Shed references clinical trial results for Wegovy in its marketing copy while noting results may vary and that a licensed clinician must find treatment appropriate. Omzo explicitly warns that user results do not represent clinical outcomes and that eligibility and results are not guaranteed.
Check Omzo eligibility details
Conclusion: choosing between Shed and Omzo
In the Shed vs Omzo comparison, Shed stands out for offering both name-brand and compounded GLP-1 together plus integrated continuous coaching and a fast 2-minute assessment, along with a 10% first month offer. Omzo is positioned as clinician-guided compounded care with lower listed starting prices for semaglutide and a model where branded scripts must be filled separately by patients. Both require clinician review and note compounded medications are not FDA-approved.
Choose Shed if…
You want integrated continuous coaching alongside GLP-1 treatment and the option to choose between FDA-approved name-brand medications and compounded alternatives, and you value a fast 2-minute assessment plus a first month promotion.
Choose Omzo if…
You prefer clinician-guided compounded semaglutide or tirzepatide plans with lower advertised starting prices and want to confirm eligibility, pharmacy, state coverage, and renewal terms before enrolling.